| INTRODUCTION
In comparison to the general US population, obesity rates are higher among Veterans. 1 Due to high rates of obesity and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) affects nearly 1 in 3 Americans and is now the leading cause of chronic liver disease. 2 A recent Veterans Health Administration (VHA) study reported a nearly 3-fold increase in NAFLD prevalence between 2003 and 2011, with more than 1 in 5 patients at high risk for advanced fibrosis. 3 In the US, NAFLD is currently the third most common chronic liver disease cause for liver transplantation and continues to increase. 4 In the VHA, NAFLD is also the third most common disease associated with hepatocellular carcinoma (HCC), even in the absence of cirrhosis. 5 VHA leadership has targeted NAFLD as an emerging challenge. 6 NAFLD encompasses a disease spectrum ranging from simple steatosis or non-alcoholic fatty liver (NAFL), to non-alcoholic steatohepatitis (NASH) (i.e. steatosis with hepatocellular injury) with or without fibrosis, cirrhosis and disease complicated by HCC, 7 in the absence of alcohol and secondary causes of hepatic fat accumulation. In validated NAFLD scoring systems, fibrosis stage ranges from absent (stage 0) to cirrhosis (stage 4). 7, 8 In paired-biopsy studies of fibrosis progression, both NAFL and NASH progress, yet fibrosis is much more prevalent and progressive in NASH. 9 Identification of NASH and high histologic NAFLD Activity Score do not predict overall mortality. 10 Advanced fibrosis (stage 3-4) is the most important predictor of NAFLD overall mortality and liver-related events. 2, [10] [11] [12] [13] In addition to the importance of fibrosis, racial and ethnic differences in NAFLD must be evaluated. Relative to Whites, Hispanic patients exhibit a significantly higher prevalence of NAFLD, while
Blacks have a lower prevalence. 14 While predominantly comprised of older White men, the VHA patient population includes approximately 10% women, 12% Blacks, 6% Hispanics and 4% other ethnicities. 15, 16 Contributing to racial disparities in NAFLD, the VHA population of women, Blacks, Hispanics and other ethnicities are projected to double by 2040. 15 Additional risk factors for NAFLD fibrosis progression include older age, male gender, and components of the metabolic syndrome, such as central obesity, hypertension, insulin resistance, and dyslipidemia. 8 Unfortunately, NAFLD/NASH often advances unnoticed to cirrhosis due to low awareness of patients at risk for progression. 17 To enhance early interventions, it is critical to identify NAFLD earlier and to better characterise its risk factors for disease progression.
Veterans have unique exposures (e.g. Agent Orange), as well as high rates of smoking and depression, which may affect NAFLD progression. 18 Due to its growing burden, NAFLD identification and risk stratification is particularly important in the VHA.
As the largest US integrated health system, the VHA could potentially improve patient outcomes with a wide-scale NAFLD clinical management program, categorising patients by risk. To accomplish this, VHA-specific risk factors for NAFLD and advanced fibrosis must be evaluated to better characterise patients at risk for adverse NAFLD outcomes, particularly liver cancer, need for liver transplantation, and death. Liver biopsy accurately assesses NAFLD fibrosis stage. 14 In this study, we evaluated and characterised risk factors for advanced fibrosis in biopsy-proven NAFLD, using VHA administrative databases.
| MATERIALS AND METHODS

| Study design and data source
We performed a retrospective case-control study using nationally Institutional Review Boards approved this study protocol.
| Patient population
Identified in the CDW, the study population included adults ( ≥ 18 years) who had a liver biopsy during January 2005 to September 2015. If the patient met inclusion criteria, the first liver biopsy during this study window was selected as the index biopsy. As only 36 of 399 (9.0%) of patients had more than one biopsy during the study period, only the index biopsy data is presented. Using ICD-9
codes and laboratory results from 1-year prior to the index biopsy, patients with the following conditions were excluded: alcoholic liver disease, alpha-1-antitrypsin deficiency, autoimmune hepatitis, druginduced liver injury, hemochromatosis, hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, and Wilson's disease.
Patients with excess alcohol use were excluded by ICD-9 codes for alcohol dependence and abuse, as well as by AUDIT-C scores ≥3 for women and ≥4 for men. 3, 20 We developed a DatStat Illume TM data collection platform survey (Data S1, S2) to record available histologic data defining NAFLD activity using a validated scale from the index liver biopsy report. 7 Laboratory tests, select medications, anthropometric data, and comorbidity data within 1 year prior to index liver biopsy were also recorded, as well as liver imaging reports within 1 year before or after the index liver biopsy. Most liver biopsies were obtained percutaneously, with either ultrasound or CT guidance. Liver biopsies were reviewed by local pathologists only. To be included in the study group, all NAFLD (without HCC) and most control liver biopsies (see description of controls below) were ≥15 mm (and of median size ≥22 mm) and had fibrosis clearly staged. 7 A liver biopsy of ≥15 mm was required to most accurately detect fibrosis and NASH. 21, 22 Based on the pathologist's interpretation, we divided NAFLD patients into four histological groups: NAFL, NASH without fibrosis, NAFLD/NASH stage 1-3 fibrosis, and NAFLD/NASH cirrhosis.
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For control category inclusion, two groupings were required to achieve sufficient numbers: (1) 
| Statistical analysis
Baseline characteristics of the control group and each successive NAFLD phenotype were adjusted for sex, race/ethnicity, age, and BMI and were compared using analysis of variance for continuous ALT ratio, hypertriglyceridemia and smoking status (current, prior or never smoker). These variables were determined by pathophysiologic relevance, evidence in earlier NAFLD models, 11, 23, 24 and distribution in our dataset. Model predictors also included the components of metabolic syndrome: hypertension, diabetes mellitus and BMI (as a surrogate for obesity). Given the NAFLD histology range observed and low case numbers, NAFLD patients with HCC were excluded.
Statistical analyses were performed using Stata 15 (STATACORP LLC, College Station, TX, USA). Coefficients from the multinomial logistic regression were exponentiated to provide the generalised odds ratio.
The generalised odds ratio provides a measure of how the probability of being in NAFLD category j (i.e. NAFLD steatosis, NASH without fibrosis, NAFLD/NASH with Stage 1-3 fibrosis, and NAFLD/ NASH cirrhosis) versus being in the control condition (j = 1) for a given value of X (e.g. has diabetes, White-non-Hispanic, etc.) differs for a 1 unit increase in X.
As a sensitivity analysis, a multinomial logistic regression was also performed on a sample limited to White American patients.
| RESULTS
Of the 2091 patients reviewed, 399 met all inclusion criteria and were included in the final analyses ( Figure 1 We then examined the effects of toxicologic, pharmacologic and other exposures on NAFLD progression. We found no association of Agent Orange exposure (0%-4.3%) or HIV (0%-2.4%) with any NAFLD category (data not shown). In all NAFLD groups, diet and exercise program use (12.3%-19.5%) was uncommon, as was bariatric surgery (0%-2.6%, data not shown). Tobacco use was generally similar across NAFLD categories. Vitamin D deficiency (13.6%-23.4%) was not associated with any NAFLD category. Vitamin E supplement use (≤10.0%) was infrequent amongst non-diabetic NAFLD patients (data not shown). Across all NAFLD groups, thiazolidinedione (pioglitazone and rosiglitazone) treatment was uncommon (<7.2%; data not shown).
Used in variceal bleeding prophylaxis, beta-blockers were prescribed more commonly in NAFLD cirrhotics compared to patients with NAFLD/NASH with fibrosis. Statin use (≥37.3%) was common in all groups. Of those patients with hypertension and/or diabetes, an ACE-inhibitor or ARB was prescribed in >58% of NAFLD patients with any degree of fibrosis.
We evaluated liver imaging in all patients. Liver ultrasound was the most common imaging modality performed for all patients with NAFL/NASH, except in those with HCC, for whom the CT scan was the most frequently performed (Table 3 The multinomial regression analysis revealed that men, relative to women, had a 3.84 (95% CI, 1.04-14.13) increased odds of being in the NAFL steatosis group than in the control group (Table 5 ). Relative to White non-Hispanic patients, Hispanic patients were 18.52 (95% CI, 1.79-192.0) times more likely to be in the NASH without fibrosis group than the control group. Higher BMI was associated with a higher odds of being in each of the NAFLD categories relative to the controls. A unit increase in BMI was associated with a 28% to a 40% increase in the odds of being in a NAFLD category relative to the control group.
Patients with diabetes had a fourfold increase in the odds of being in the NASH without fibrosis group relative to the control group, an eightfold increase in the odds of being in the NAFLD/NASH with fibrosis group relative to the control group, and nearly 12-fold increase in being in the NAFLD/NASH with cirrhosis group relative to the control group. Patients with hypertension had lower odds of being in the NAFL group, the NASH without fibrosis group, or the NAFLD/NASH with fibrosis group than being in the control group. Relative to patients without hypertriglyceridaemia, patients with hypertriglyceridemia had a Statistical significance key: adjusted for multiplicity P < .00147.
higher odds of being in the NAFL group, the NASH without fibrosis group, or the NAFLD/NASH with fibrosis group than being in the control group. When a multinomial logistic regression was performed in
White Americans only, all findings remained significant and of consistent magnitude with the overall analysis.
| DISCUSSION
In our retrospective case-control VHA study of nearly 400 patients with well-characterised control and NAFLD liver biopsies, we found that predictors for advanced NAFLD fibrosis among these veterans were diabetes mellitus, body mass index, AST/ALT ratio, and hypertriglyceridemia. In this predominantly White male population, more than two of three patients with NAFLD fibrosis or HCC exhibited diabetes mellitus, hypertension or metabolic syndrome. The proportion of Hispanic veterans with NASH was notable. We did not find an effect of smoking or depression on NAFLD progression.
While all NAFLD categories exhibited obesity, severe obesity was observed in NAFLD with advanced fibrosis/cirrhosis. A 5%-10% weight loss is effective in improving NAFLD steatosis and necroinflammation. 14 Despite the high prevalence of diabetes and severe Statistical significance key: adjusted for multiplicity P < .0038. the cost-effective diabetes prevention program (DPP) successfully yielded an average 7% weight loss and 58% decrease in the incidence of diabetes in a racially diverse population. 25, 26 In a VHA pilot study of DPP, preliminary findings revealed promising weight loss. 27 Among nearly 1800 VHA patients undergoing Roux-en-Y gastric bypass surgery for severe obesity compared to nonsurgical matched patients, a 21% weight loss was sustained at a 10 year follow-up. 28 Bariatric surgery has been reported to decrease NASH and NAFLD fibrosis. 29 While NAFLD can improve with weight loss, few patients received obesity interventions, yet most had multidisciplinary care (e.g. Primary Care, GI/Hepatology, Endocrinology, Cardiology, etc.).
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This suggests the need for creative new NAFLD solutions, such as a Healthy Lifestyles Clinic led by dieticians and exercise coaches to enhance nutrition and physical activity. To catalyze health behavior changes, providers can collaborate with veterans on action plans, 30, 31 provide education, and address barriers. Sustained behavioral change is generally socially rooted. In veterans with diabetes, peer support groups significantly improved glycemic control, particularly among those with initially low medication adherence. 32 To maximise convenience and use, clinics could be onsite, virtual, or community-based.
While the Veterans Choice Program enables community-based care,
close VHA collaboration will be needed. A VHA-based care model for NAFLD would ultimately seek to improve outcomes by optimizing communication with the patient and all providers, enhance access to clinical trials, and promote systematic data collection to aid in large-scale research endeavours.
Without interventions to address obesity and diabetes, NAFLD may progress to cirrhosis and HCC. HCC can even develop in noncirrhotic liver, as we observed in this study. In our NAFLD population, we noted high rates of liver imaging, particularly in cirrhotic patients-in whom nearly all had liver imaging within a year of their biopsy diagnosis, likely for HCC screening. Although our numbers were limited, our NAFLD and HCC group reflected the NAFLD spectrum-from steatosis to cirrhosis, as earlier observed in the VHA. 5 Particularly in the presence of obesity and diabetes, HCC arises in association with underlying inflammation, oxidative stress, lipid peroxidation, apoptosis and liver regeneration, and patatin like phospholipase domain containing 3 (PNPLA3) GG genotype (rs738409). 33, 34 Relative to Whites, the PNPLA3 GG genotype is most prevalent in Hispanics and least prevalent in Blacks [34] [35] [36] ; this variant is associated with susceptibility to necroinflammation and fibrosis. 35 The prevalence of diabetes is 1.7-fold higher in Hispanics and
Blacks, relative to Whites in the US. 37 In the VHA, minority populations are projected to increase. 16 Our study aligns with earlier findings revealing health disparities in NAFLD, with a higher prevalence reported in Hispanics 37 and a lower prevalence in Blacks. 14 Paralleling our study, earlier NAFLD studies report diabetes mellitus to be a significant predictor of advanced hepatic fibrosis, even in predominantly female populations. 38 Similarly, other studies examining liver biopsies report the prevalence of metabolic syndrome or BMI increase with NAFLD progression, 39 and an increasing AST/ALT ratio elevates risk of NAFLD cirrhosis. 11, 23 Hypertriglyceridemia has also been reported as a risk factor for NASH, 40 and was found to increase the risk of NAFL, NASH, and NAFLD with fibrosis in our study. In contrast to some, 41, 42 but not all earlier studies 2, 43, 44 reporting a positive association with smoking, we found no association of smoking and NAFLD progression.
While liver biopsy is termed the "gold standard" for NAFLD diagnosis, 14 it is encumbered by morbidity and sampling variability. 21, 45 Hence, NAFLD fibrosis is increasingly quantified by safe noninvasive measures: clinical prediction rules, 8, 46, 47 such as the validated NAFLD fibrosis score, 12 transient elastography, and magnetic resonance elastography. Furthermore, while a VHA study of natural history of NAFLD could further refine our understanding of risk factors, such a study is becoming increasingly challenging with the move to fewer liver biopsies and more noninvasive follow-up of NAFLD patients. 48 Our study therefore complements innovative VHA electronic medical record (EMR) algorithms developed and validated to identify NAFLD patients with ALT elevations. 3, 49 Application of these NAFLD algorithms in the VHA has informed NAFLD epidemiologic trends over time. 3 The NAFLD fibrosis score 11 has been demonstrated to stratify low-and high-risk NAFLD patients for intervention more cost-effectively than liver biopsy. 47 Further modeling of our data may enable VHA-customised EMR algorithms to potentially enable "real time"
identification of NAFLD patients at highest risk of advanced fibrosis for immediate intervention and triage to specialist care.
Utilising another systemic approach, the VHA has very successfully used patient registries to identify and track patients for intervention and treatment. 50 While approved NAFLD pharmacologic treatments
are not yet available, potential treatments are progressing. 51 Our findings reveal the VHA NAFLD population to be similar to NAFLD populations in earlier non-veteran studies, 6 Our study is limited by selection bias. We only included patients with biopsy-proven NAFLD or normal liver, and patients subjected to biopsy may not be representative of the overall VHA population.
Reflecting the VHA population, our study population was predominantly male and has limited generalisability to the larger NAFLD population as females more frequently develop NASH. 52 Some patients were enrolled in clinical trials at academic centers, which may have introduced bias or affected the racial/ethnic composition. Liver biopsies were reviewed by local pathologists; no centralised study pathologist review was performed. This limitation was ameliorated by our stringent histologic inclusion criteria and 22 mm median biopsy size enabling accurate fibrosis staging. As liver ultrasound may be less sensitive for HCC surveillance in obesity, 53 we may have missed some HCC (however, this was mitigated by CT or MRI imaging in nearly half of all patients). To maximise data quality, we excluded many cases with ambiguous, incomplete or inadequate histologic data. Although recorded when available, we found low rates of Agent Orange exposure and incomplete data on the number of pack years smoked, which limited our analyses.
As the leading cause of chronic liver disease in the US, NAFLD is of increasing clinical concern in the VHA. 3 In our national VHA study, we characterised NAFLD and identified risk factors for advanced fibrosis. We found that features associated with NASH and advanced fibrosis in our veterans were nearly identical to the non-veteran population. For example, diabetes and BMI best predicted advanced fibrosis, Hispanics were more likely to have NASH, Blacks exhibited low rates of NAFLD and advanced fibrosis, and current or prior tobacco use had no significant impact on NAFLD progression. Despite severe obesity and high rates of comorbidity, patients with NAFLD fibrosis were seldom enrolled in a diet or exercise program, and very uncommonly had bariatric surgery. To better identify patients and track behavioral and lifestyle interventions, a NAFLD registry could prove useful. Alternatively, use of "real-time" electronic medical record algorithms at point of care may enhance VHA care. Our findings can now be applied to better tailor NAFLD screening, categorisation, and treatment in the VHA.
AUTHORSHIP
Guarantor of the article: Dr. Christine Hunt
Author contributions: YP contributed to research design, data acquisition, data analysis, data interpretation, and drafted the paper.
All authors approved the final version of the article. EG contributed to research design, data analysis, data interpretation, and critical draft revision.
LG contributed to research design, data acquisition, data interpretation, and critical draft revision. RM contributed to research design, data analysis, data interpretation, and critical draft revision. MT contributed to research design, data acquisition, data interpretation, and critical draft revision. BH contributed to research design, data acquisition, data interpretation, and critical draft revision. DP contributed to research design, data analysis, data interpretation, and critical draft revision. SS contributed to research design, data analysis, data interpretation, and critical draft revision. CM contributed to research design, data acquisition, data interpretation, and critical draft revision. CH contributed to research design, data acquisition, data analysis, data interpretation, and critical draft revision. All authors approved the final version of the article.
ACKNOWLEDG EMENTS
The authors wish to thank Ayako Suzuki, George Ioannou, Folasade 
